TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03121248

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,7Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,7Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,7Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,7Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LNI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,4Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LNI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,4Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LNI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,4Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LNI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LNI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LNI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB 5 fractions if needed
Description: Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB 5 fractions if needed
Description: Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB 5 fractions if needed
Description: Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
Study: NCT04405258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left posterior wall isolation
Description: Pulmonary vein isolation, superior vena cava isolation, cavotricuspid isthmus ablation, and left posterior wall isolation
Study: NCT03121248

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB 5 fractions if needed
Description: Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB 15 fractions if needed
Description: Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
Study: NCT02579629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.1%
Description: Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
Study: NCT03121248

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB 15 fractions if needed
Description: Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB 15 fractions if needed
Description: Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB 15 fractions if needed
Description: Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TWI 5 fractions
Description: External beam radiotherapy in 5 fractions of 5,7Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TWI 15 fractions
Description: External beam radiotherapy in 15 fractions of 2,67Gy
Study: NCT01708304

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RDAD
Description: Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
Study: NCT04144101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Etoricoxib 60 mg QD Oral
Study: NCT02579629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
Study: NCT04144101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100 mg BID Oral
Study: NCT01593956

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: tDCS

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: tDCS
Study: NCT01452373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA and Acolbifene
Description: DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
Study: NCT01145898

Intervention type: DRUG
Intervention: (Cosopt®, prostaglandin)
Description: We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
Study: NCT02579629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Q ® elastomeric pump
Description: The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Q ® elastomeric pump
Description: The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-Q ® elastomeric pump
Description: The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
Study: NCT02884908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin plus BBCET
Description: Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin plus BBCET
Description: Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus BBCET
Description: Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus BBCET
Description: Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
Study: NCT00254046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMC125
Description: 2 X100 mg tablets b.i.d.96 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets b.i.d.96 weeks
Study: NCT02854878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Lucy ultrasonic comb models A and B combined with the LucyGel
Study: NCT04061044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic Insert
Description: Travoprost, 0.32 mg
Study: NCT04602559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIDERM Panty group
Description: In the MOBIDERM Panty group, patients wear the MOBIDERM Panty during day and night for 3 months with the possibility to add the PAD.~The protocol includes 3 visits.~Visit 1 at day 0, corresponding to the inclusion visit, includes device delivery and some clinical evaluations (clinical examination, characteristics of lymphedema, self questionnaires, pain assessment, perimeter data).~Visit 2 at 30 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).~Visit 3 at 90 days after the inclusion : includes some clinical evaluations (clinical examination, characteristics and evolution of lymphedema, self questionnaires, pain assessment, perimeter data, safety, compliance).
Study: NCT01923090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride 5mg once daily for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride 0.5mg once daily for 3 weeks
Study: NCT02631824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open reduction and internal fixation
Description: Open reduction and internal fixation using an intramedullary nail
Study: NCT05697913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continued treatment adapted to the response
Description: Instead of receiving a pre-specified number of treatment cycles, regardless of the result obtained, in the MRDI-driven treatment group patients continue receiving treatment until reaching a complete remission with negative MRD and Image, changing the therapeutic line if it is not obtained with the line current therapy. In this group of the patients the treatment was stopped only when this degree of deep response was achieved.
Study: NCT01082029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
Study: NCT02631824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction and internal fixation
Description: Open reduction and internal fixation using an intramedullary nail

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFNA
Description: Trochanteric Femoral Nail Advance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TFNA
Description: Trochanteric Femoral Nail Advance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmentation (Cement)
Description: Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
Study: NCT04629469

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperfine MRI
Description: • Patients who have a standard of care MRI, CT or US will undergo a low-field MRI utilizing Hyperfine either at the patient's bedside or in the department of Radiology. Results of the Hyperfine MRI will not be used for clinical care and will only be available to members of the research team for review.
Study: NCT01744795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: induced changes in hemodynamics
Description: Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
Study: NCT04479267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT01451827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 50/80 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan MR
Description: 50/80 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan IR
Description: 60/30 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study: NCT04454775

Intervention type: DIAGNOSTIC_TEST
Intervention: coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.

Intervention type: DIAGNOSTIC_TEST
Intervention: coagulation system parameters; factor 8, von Willebrand factor, protein C, protein S, antithrombin III and fibrinogen were studied.
Study: NCT01579500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Subcutaneous injection of botulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Subcutaneous injection of normal saline
Study: NCT01964924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor GSK2141795
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04720443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablet
Description: NIP292 (oral tablet at 10 mg) or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablet
Description: NIP292 (oral tablet at 30 mg) or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablet
Description: NIP292 (oral tablet at 100 mg) or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablet
Description: NIP292 (oral tablet at 300 mg) or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablet
Description: NIP292 (oral tablet at 500 mg) or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablets
Description: NIP292 (oral tablet at dosage 1) or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIP292 tablets
Description: NIP292 (oral tablet at dosage 2) or placebo
Study: NCT02516072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RIPC
Description: IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
Study: NCT04936893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Practice
Description: 10-15 mins of daily mindfulness practice using HeadSpace, for 3 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: 10-15 mins of cognitive games using Lumosity, for 3 weeks
Study: NCT02090296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02352857

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: 100g of sponge cakes made with 24g of dextrose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOS
Description: 100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
Study: NCT04447859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Slow semaglutide titration group vs. label recommended titration group (16-week flexible vs. 8-week semaglutide titration)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: label recommended titration
Description: label recommended titration
Study: NCT01482923

Intervention type: BEHAVIORAL
Intervention: Treatment as usual
Description: Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.

Intervention type: BEHAVIORAL
Intervention: AIR (Aspirations, Inspiration, Respiration)
Description: Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
Study: NCT02145559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT03162562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oregovomab
Description: Monoclonal antibody against CA 125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Immune adjuvant
Study: NCT02843061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each time 10 billion cells, 4 times in all,i.v.
Study: NCT02682277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polygucosamine
Description: 2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
Study: NCT03090139

Intervention type: DRUG
Intervention: Anti-TNF Therapy
Description: Anti-TNF therapy.
Study: NCT04138264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative opioid counseling
Description: preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
Study: NCT01127763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT00391859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)
Description: See Detailed Description.